Regulator of G-protein signaling 2 (RGS2) negatively regulates the signaling of G-protein-coupled receptors, such as the angiotensin II (AngII) type 1 receptor by accelerating the inactivation of Gaq. Rgs2-deficient mice show increased sensitivity and prolonged responsiveness to vasoconstrictors, and genetic variations in the RGS2 gene are associated with hypertension in humans. This study aimed to clarify whether Rgs2 deficiency contributes to the development of vascular remodeling and therapeutic efficacy of the angiotensin receptor blocker telmisartan on atherosclerotic vascular damage. We treated Rgs2 +/+ , Rgs2 +/À and Rgs2 À/À mice with saline (control group), AngII (1000 ng per kg per min, AngII group) or low-dose telmisartan (0.3 mg per kg per day) with AngII infusion (AngII+Telmi group) for 4 weeks. For all genotypes, the AngII groups exhibited significantly higher blood pressure, a higher mortality rate and a higher incidence of aortic aneurysm than the respective control group. Interestingly, aneurysm incidence was decreased in the AngII+Telmi group compared with the AngII group in Rgs2 À/À mice (6.7 vs. 42.9%, Po0.05), but not in Rgs2 +/+ mice (38.9 vs. 40.0%). Moreover, in Rgs2 À/À mice, the AngII+Telmi group exhibited significant improvement in survival, reduction of enlarged aortic diameter, inhibition of superoxide production and suppression of NAD(P)H oxidase activity compared with the AngII group. Thus, Rgs2 deficiency potentiates the vascular protection effect of low-dose telmisartan. Our results suggest that angiotensin receptor blocker may be useful for protection from cardiovascular events in hypertensive subjects with risk alleles in the RGS2 gene.
INTRODUCTION
The renin-angiotensin system has an important role in the regulation of blood pressure and vascular structure. Angiotensin II (AngII) is a potent vasoconstrictor that elevates blood pressure through a G-protein-coupled receptor, angiotensin type 1 receptor (AT1R). AngII generates aldosterone at the adrenal gland and activates the sympathetic nervous system, leading to blood pressure elevation. In addition to the effects of AngII on the elevation of blood pressure, evidence has revealed that it has a role in atherogenesis. In animal models, chronic infusion of AngII promotes the formation of atherosclerotic lesions and aneurysms. 1,2 It is widely known that AngII-induced NAD(P)H oxidase activation increases the production of reactive oxygen species from various cell types, 3 including endothelial cells, vascular smooth muscle cells and monocytes/macropharges, and promotes inflammation in atherosclerotic lesions. 4 Regulator of G-protein signaling 2 (RGS2) is present in many cardiovascular tissues, including the heart, kidney and blood vessels, and it is required for normal vascular function and regulation of blood pressure. 5 RGS2 negatively regulates the signaling of G-proteincoupled receptors, such as AT 1 R, by accelerating the inactivation of Gaq by its guanosine triphosphatase-activating protein activity. RGS2 also mediates the nitric oxide-cyclic guanosine monophosphate pathway to decrease vascular resistance and attenuate vasoconstrictor signaling in vascular smooth muscle cells. 5, 6 Patients with Bartter's and Gitelman's syndromes have hypotension with an enhancement of RGS2 expression. 7 Taken together, silencing of the RGS2 gene disrupts these pathways and enhances the vasoconstrictor signaling.
The first reported phenotypes of Rgs2-deficient mice were the reduction of T-cell activation, the control of synapse development in the hippocampus and an increase in anxiety responses. 8 With respect to the blood pressure regulation, Rgs2-deficient mice exhibit a hypertensive phenotype and persistent constriction of the resistance vasculature. 5, 9 This hypertensive phenotype differs in degree according to conditions such as age in weeks, anesthesia, postoperative recovery, restrained stress, time zone and apparatus for blood pressure measurement. 5, 9, 10 Together with another group, we have reported that genetic polymorphisms within the human RGS2 gene are associated with hypertension. [11] [12] [13] [14] It has been speculated that genetic variations may reduce RGS2 function. 15, 16 Because hypertension contributes to the pathogenesis of cardiovascular disease, it is hypothesized that genetic variations in RGS2 might be a risk factor for the development of atherosclerosis through enhancement of AngII signaling.
Telmisartan is an angiotensin receptor blocker (ARB) with a longer half-life and higher lipophilicity than other ARBs, 17 and it is a commonly used medication for the treatment of hypertension. In a recent clinical trial, 18, 19 telmisartan resulted in the prevention of vascular events such as myocardial infarction and stroke. Therefore, telmisartan is expected to be effective for cardiovascular protection in Rgs2-deficient mice that have enhanced AngII signaling.
In this study, we investigated the effects of RGS2 deficiency on the development of vascular remodeling and the therapeutic efficacy of low-dose telmisartan on atherosclerotic vascular damage resulting from excessive stimulation of AT 1 R by RGS2 deficiency.
METHODS Mice
Rgs2-deficient mice on the C57BL/6 background were provided by Dr Michael E Mendelsohn (Tufts University School of Medicine). 8 Mice were kept in a specific pathogen-free barrier under constant temperature conditions and housed on a 12-h light/12 h dark cycle. All experiments were approved by the Animal Care and Use Committees of the National Cardiovascular Center, Japan, and they were performed in accordance with the guidelines.
Drug administration
We used 18-week old male Rgs2-deficient (Rgs2 À/À , Rgs2 +/À ) and wild-type (Rgs2 +/+ ) mice and divided them into three treatment groups. Mice were subcutaneously infused with AngII (1000 ng per kg per min, AngII group), or saline containing 0.3% bovine serum albumin (control group) using an ALZET Micro-Osmotic Pump (model 1004, Durect, Cupertino, CA, USA) for 4 weeks. Mice were also treated with AngII (1000 ng per kg per min) and low-dose telmisartan (0.3 mg per kg per day, AngII+Telmi group). Telmisartan was administered in drinking water. We adopted a low dosage of telmisartan that does not affect blood pressure. 20 
Hemodynamic analysis
Systolic blood pressure and heart rate were measured in conscious, prewarmed, and restrained mice by the tail-cuff method using a non-invasive blood pressure measuring device (BP98-A, Softron, Tokyo, Japan) before treatment and on days 7, 14, 21 and 28 after treatment just around the same time of day. For stable measurement, tail-cuff pressures were obtained after a 2-week-training period to acclimatize the mice to the restraining device and cuff inflation. The pulse waveform was monitored in real time using the BP98AW software (version 2.12, Softron). The first 10 measurements were excluded from the analysis, and at least 5 measurements with an untroubled pulse waveform were collected.
Biochemical examination
After 4 weeks of treatment, overnight fasting blood was collected from anesthetized mice and put into capillary blood collection tubes including a gel/clot activator (Capiject tube, Terumo Medical, Somerset, NJ, USA). Serum was obtained by the manufacturer's instructions and stored at À80 1C in aliquots before use. Serum levels of blood urea nitrogen, creatinine, aspartate aminotransferase, alanine aminotransferase, lactate dehydrogenase, low-density lipoprotein-cholesterol and glucose were measured using a Hitachi clinical analyzer (model 7180, Hitachi High-Technologies, Tokyo, Japan).
Aortic tissue collection and morphometric analysis
Dissection was performed under anesthesia after blood collection. After thoracolaparotomy, the inferior vena cava was cut for exsanguination and the aorta was perfused with ice-cold saline through the left ventricle. The aortic root and heart were subsequently eviscerated, and the periadventitial tissue was dissected away under a stereomicroscope. The external diameters in the middle of the suprarenal abdominal aorta between the diaphragm and renal artery bifurcation were measured using the ImageJ software (version 1.40, National Institute of Health, Bethesda, MD, USA). After taking the images, the aorta was cut into thoracic and abdominal regions. The thoracic aorta was immediately frozen by liquid nitrogen and stored at À80 1C for the measurement of NAD(P)H oxidase activity. The suprarenal abdominal aorta was cut into two pieces. For detection of superoxide production, the superior half was immediately embedded in OCT compound (Sakura Finetek Japan, Tokyo, Japan) in liquid nitrogen and stored at À80 1C. For immunohistochemical staining, the inferior half was fixed with 4% paraformaldehyde overnight and paraffin embedded.
Detection of aortic superoxide production
Aortic superoxide levels were measured with dihydroethidium (Invitrogen Molecular Probes, Carlsbad, CA, USA) on cross sections (9 mm) obtained from the unfixed frozen blocks of abdominal aorta, as previously described. 21 The unfixed frozen sections were stained by dihydroethidium (2 mM, 30 min, 37 1C) in a dark humidified chamber and washed briefly. The images were captured with a laser scanning confocal fluorescent microscope (FLUOVIEW system, Olympus, Tokyo, Japan). For the quantification of ethidium fluorescence, the mean fluorescence intensity (fluorescence intensity per unit area) in the aortic wall was calculated using the ImageJ software on high-power (x300) images.
Measurement of NAD(P)H oxidase activity
The frozen aortic segments were homogenized using a Sample Grinding Kit (GE Healthcare UK, Buckinghamshire, England). After centrifugation, the supernatant was stored at À80 1C until use. Protein concentrations were measured by the BCA protein assay kit (Pierce Biotechnology, Rockford, IL, USA). The enzymatic activity of NAD(P)H oxidase of the homogenates was measured by lucigenin-enhanced chemiluminescence, as previously described. 20 The assay solution contained lucigenin (250 mM) as an electron acceptor and NADH (100 mM) or NADPH (100 mM) as a substrate. After pre-incubation at 37 1C for 20 min, the reaction was started by adding 50 mg of homogenate. Photon emissions were continuously recorded for 15 min with a chemiluminescence reader (BLR-201, ALOKA, Tokyo, Japan). The chemiluminescent signals observed in the absence of homogenates were subtracted from the signals of the samples. The signal was corrected for the protein concentration of each homogenate and expressed as counts per minute by mg protein for a 15-min period. In some experiments, the homogenates were pre-incubated with 10 mM diphenyleneiodium, a selective NADPH oxidase inhibitor, for 20 min before the lucigenin-enhanced chemiluminescence measurements.
Statistical analysis
Data are expressed as mean±s.e.m. All statistical analyses were performed using the Prism software (version 5.0, GraphPad Software, La Jolla, CA, USA). Hemodynamic changes were analyzed by two-way analysis of variance during the period of administration. Differences between multiple groups were analyzed by one-way analysis of variance or Kruskal-Wallis test in the case of a non-Gaussian distribution, followed by the Bonferroni post-hoc test for comparison between treatment groups or genotype groups. The log-rank (Mantel-Cox) test was used for statistical analysis of survival curves, and the w 2 -test was used to compare the incidence of aneurysm. Values of Po0.05 were considered statistically significant.
RESULTS

Changes in blood pressure
To elucidate the direct role of AngII signaling in Rgs2-deficient mice, we divided Rgs2 +/+ , Rgs2 +/À and Rgs2 À/À mice into three treatment groups: the control group, the AngII group and the AngII+Telmi group. Drug administration was performed for 4 weeks, and hemodynamic changes were measured. In all Rgs2 genotypes, the AngII group exhibited B50 mm Hg higher systolic blood pressure than the control group (Po0.001) (Figure 1 ). Rgs2 dysfunction was expected to enhance the AngII signaling, leading to higher blood pressure in RGS2 deficiency and ARB responses S Matsumoto et al Rgs2 À/À mice, but there were no blood pressure differences among the Rgs2 genotypes in the AngII group. Moreover, the AngII+Telmi group did not show reduced blood pressure in any of the genotypes. Before drug administration, there were no significant differences in blood pressure among the Rgs2 genotypes in our experimental condition using the tail-cuff method. Both the AngII and the AngII+Telmi groups showed no differences in heart rate among the genotypes (data not shown). Although Rgs2 À/À mice tended to show a lower body weight than the other genotypes, drug administration did not affect the body weight (data not shown).
Survival rates and blood biochemical examinations Some mice died during the period of administration mainly because of the cardiovascular events, including the rupture of aneurysms. Therefore, we compared the survival curves in mice with all Rgs2 genotypes and with the three treatment groups. As shown in Figure 2 , AngII treatment decreased the survival rate for all the Rgs2 genotypes compared with the control group, but there were no significant differences in survival rate among the Rgs2 genotypes in the AngII group. Interestingly, Rgs2 À/À mice treated with AngII+Telmi had significantly improved survival compared with Rgs2 À/À mice treated with AngII alone (Po0.05).
As shown in the Table 1 , blood urea nitrogen levels were significantly increased in the AngII and AngII+Telmi groups compared with the control group (Po0.05). Creatinine levels also tended to increase in the AngII group compared with the control group. These results indicated the exacerbation of renal function caused by AngII-induced hypertension in all Rgs2 genotypes. Recent studies have shown that telmisartan improves the metabolism of lipids and glucose. 22, 23 Our study showed that low-density lipoprotein-cholesterol levels were significantly decreased in the AngII+Telmi group compared with the Figure 1 Blood pressure changes in response to AngII or AngII plus telmisartan. Systolic blood pressure (SBP) variations were shown in Rgs2 +/+ , Rgs2 +/À and Rgs2 À/À mice. Mice were divided into three groups, control group (saline), AngII group (AngII, 1000 ng per kg per min) and AngII+Telmi group (AngII, 1000 ng per kg per min, telmisartan, 0.3 mg per kg per day). Results are expressed as mean ± s.e.m. in the control group (Rgs2 +/+ : n¼8, Rgs2 +/À : n¼8, Rgs2 À/À : n¼8), the AngII group (Rgs2 +/+ : n¼17, Rgs2 +/À : n¼25, Rgs2 À/À : n¼15) and the AngII+Telmi group (Rgs2 +/+ : n¼14, Rgs2 +/À : n¼15, Rgs2 À/À : n¼15). The AngII and AngII+Telmi groups showed significantly higher SBP than the control group (Po0.001). Figure 2 Comparison of survival curves in mice treated with AngII or AngII plus telmisartan. The treatment design was the same as that in Figure 1 . The survival rate is expressed as a percent of animals in the control group (Rgs2 +/+ : n¼8, Rgs2 +/À : n¼8, Rgs2 À/À : n¼9), the AngII group (Rgs2 +/+ : n¼20, Rgs2 +/À : n¼28, Rgs2 À/À : n¼21) and the AngII+Telmi group (Rgs2 +/+ : n¼18, Rgs2 +/À : n¼15, Rgs2 À/À : n¼15). *Po0.05. 
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AngII group in Rgs2 À/À mice (Po0.05), whereas no changes in glucose levels were observed. Liver function, as indicated by aspartate aminotransferase, alanine aminotransferase and lactate dehydrogenase levels, was normal (data not shown).
Vascular remodeling
In the AngII group, B30-40% of mice had aortic aneurysms, as shown in Figure 3a . The incidence of aortic aneurysm was not different among Rgs2 genotypes in the AngII group. Rgs2 À/À mice treated with AngII+Telmi had a significantly lower rate of aneurysm formation than the AngII group (Po0.05, Figure 3b ). In Rgs2 +/À mice, the AngII+Telmi group had a lower rate of aneurysm than the AngII group. Moreover, the incidence of aortic aneurysms in Rgs2 À/À mice was significantly lower than that in Rgs2 +/+ mice in the AngII+Telmi group (Po0.05). Next, we compared the diameters of the abdominal aorta ( Figure 4 ). The AngII group showed significantly more enlarged aortic diameters than the control group for all Rgs2 genotypes (Rgs2 +/+ : Po0.05, Rgs2 +/À , Rgs2 À/À : Po0.001). Although AngII+Telmi treatment did not reduce blood pressure in any of the genotypes, it significantly reduced enlargement of the aortic diameter compared with the AngII treatment of Rgs2 À/À mice (Po0.01). In addition, in Rgs2 +/À mice the AngII+Telmi treatment tended to reduce the enlargement of the aortic diameter compared with AngII treatment alone.
Oxidative stress in vascular walls
To assess oxidative stress in the aortic wall, we measured superoxide production and NAD(P)H oxidase activity. Figure 5A shows the in situ detection of superoxide in the abdominal aorta using dihydroethidium staining in Rgs2 À/À mice. The red fluorescence intensity of the aorta in Rgs2 À/À mice tended to be more intense in the AngII group and was obviously suppressed in the AngII+Telmi group. Quantitative analysis showed that superoxide production of the aorta in Rgs2 À/À mice was significantly decreased in the AngII+Telmi group compared with the AngII group (Po0.001), whereas production in the other Rgs2 genotypes was not statistically different ( Figure 5B ). Furthermore, the NAD(P)H oxidase activity of aorta in Rgs2 À/À mice was also decreased in the AngII+Telmi group compared with the AngII group (Po0.001, Figure 5c ).
DISCUSSION
This study showed that the AngII group exhibited higher systolic blood pressure, a higher mortality rate, a higher aortic aneurysm incidence, and a more enlarged aortic diameter than the control group for all Rgs2 genotypes. Interestingly, in Rgs2 À/À mice, the AngII+Telmi group showed a significant improvement in the survival rate as well as in the suppression of vascular remodeling compared with the AngII group, although blood pressure was not changed. In parallel with this improvement of vascular phenotypes in Rgs2 À/À mice, the NAD(P)H oxidase activity and superoxide production of the aorta in Rgs2 À/À mice was decreased in the AngII+Telmi group. Thus, lowdose telmisartan could prevent AngII-induced vascular remodeling via the suppression of oxidative stress in the vascular wall of Rgs2 À/À mice.
Rgs2 dysfunction is expected to enhance the AngII signaling through AT 1 R, leading to blood pressure elevation, atherosclerotic vascular remodeling and organ damage. However, our results did not show significant differences among Rgs2 genotypes in the AngII group, including blood pressure, mortality rate, aneurysmal formation, aortic diameter and aortic oxidative stress (Figures 1-5) . The reason for the lack of differences among the Rgs2 genotypes may have been because the concentrations and dosing period of AngII may be excessive and outside the capability of Rgs2 regulation. Nevertheless, AngII was given in doses sufficient to cause the RGS2 deficiency and ARB responses S Matsumoto et al exacerbation of vascular phenotypes in all genotypes under our experimental condition. Thus, we examined the impact of Rgs2 deficiency on the therapeutic effect of low-dose telmisartan in AngII-infused mice.
The most interesting aspect of our study was the observed therapeutic efficacy of telmisartan. Low-dose telmisartan significantly improved survival, inhibited vascular remodeling such as aneurysmal formation and enlargement of aortic diameter, and decreased aortic oxidative stress in Rgs2 À/À mice. These effects, mostly observed in the aorta, were independent of blood pressure reduction and were not observed in Rgs2 +/+ mice (Figures 2-5) . In Rgs2 +/À mice, low-dose telmisartan exhibited partial therapeutic effects such as improvement of survival, inhibition of aneurysm formation and reduction of enlarged aortic diameter, although there were no significant differences (Figures 2-4) . These Rgs2 deficiency-dependent vascular protective effects of low-dose telmisartan could be explained by the following mechanisms. Some reports have shown that telmisartan and another ARB, valsartan, prevent vascular remodeling through inhibition of oxidative stress, inflammation and degradation of the extracellular matrix independent of their antihypertensive effects. 20, [24] [25] [26] Heximer et al. 9 have reported that responsiveness to another ARB, candesartan, is more sensitive in Rgs2 À/À mice than Rgs2 +/+ mice with regard to its antihypertensive and organ protection effects. Thus, vascular protective effects through inhibition of oxidative stress by low-dose ARB may be exaggerated in Rgs2 À/À mice as a result of its antagonism for excessive AT 1 R signaling. Moreover, some reports have characterized new functions of telmisartan as a partial agonist for peroxisome proliferator-activated receptors (PPARs). 22, 23, 27 Activation of PPARa by agonists or telmisartan induces an anti-inflammatory response through the repression of nuclear factor-kB signaling in umbilical vein endothelial cells and aortic smooth muscle cells in vitro 27, 28 and inhibits macrophage infiltration and reduces aortic dilatation in a mouse model of aortic aneurysm. 29 PPARa and PPARg improve lipid and glucose metabolism, respectively. 30 Low-dose telmisartan in Rgs2 À/À mice improved lipid metabolism but did not affect glucose metabolism, as shown in the Table 1 . Therefore, these protective effects of telmisartan in Rgs2 À/À mice might be dependent on the anti-inflammatory response via PPARa activation, and Rgs2 deficiency might affect enhancement of the anti-inflammatory effect of telmisartan. Taken together, these results show that the therapeutic effect of lowdose telmisartan might be higher in the aorta of Rgs2 À/À mice than in that of Rgs2 +/+ mice through both AT 1 R blockade and PPARa activation.
Hypertension is a major risk factor of cardiovascular disease. Human RGS2 genetic polymorphism is associated with the pathogenesis of hypertension in different races [11] [12] [13] [14] that may result from Gaqsignal acceleration by RGS2 dysfunction. Our mouse study did not indicate a relationship between Rgs2 deficiency and the development of atherosclerosis and aneurysm in vivo. Instead, we found that lowdose telmisartan would be beneficial in AngII-induced vascular remodeling, dependent on Rgs2 deficiency and dysfunction. This , Quantitative analysis of superoxide production in the aortic wall. For quantification of ethidium fluorescence at the aortic wall, the fluorescence intensity was calculated using the ImageJ software and is expressed in arbitrary units. (C), Effect of telmisartan on NAD(P)H dependent oxidase activity of aorta homogenates using lucigenin-enhanced chemiluminescence in Rgs2 À/À mice. NAD(P)H oxidase activity was measured as described in Methods section. As a control, NADPH oxidase inhibitor, diphenyleneiodium, reduced NADH and NADPH oxidase activities below measurable limits. Results are expressed as mean ± s.e.m. in the control group (Rgs2 +/+ : n¼5, Rgs2 +/À : n¼5, Rgs2 À/À : n¼5), the AngII group (Rgs2 +/+ : n¼11, Rgs2 +/À : n¼21, Rgs2 À/À : n¼12) and the AngII+Telmi group (Rgs2 +/+ : n¼14, Rgs2 +/À : n¼15, Rgs2 À/À : n¼15). *Po0.001.
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S Matsumoto et al study suggests that ARB might be more useful for protection from cardiovascular events in hypertensive subjects with risk alleles in the RGS2 gene than other antihypertensive drugs. This concept might be applicable for personalized medicine on the basis genetic information.
